Brasier A R, Ron D, Tate J E, Habener J F
Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston 02114.
EMBO J. 1990 Dec;9(12):3933-44. doi: 10.1002/j.1460-2075.1990.tb07614.x.
The gene encoding angiotensinogen, the glycoprotein precursor of the potent vasopressor peptide angiotensin II, is transcriptionally activated in hepatocytes during the acute-phase response through interactions of mutually cooperative glucocorticoid receptors and proteins that bind to an acute-phase response element (APRE) 5'-AGTTGGGATTTCCCAACC-3'. The APRE binds a family of constitutive proteins (BPcs) and a cytokine inducible protein (BPi) that is indistinguishable from nuclear factor kappa B (NF kappa B). The interactions of purified proteins with the APRE were studied by in vitro binding and in vivo transcriptional trans-activation assays. BPc is a family of heat-stable DNA binding proteins, the different sized members of which are capable of forming heterodimers. BPcs are recognized by anti-C/EBP antiserum and produce a footprint similar to bacterially expressed C/EBP on the APRE. BPi has a 4- to 5-fold greater affinity for the APRE than the BPcs, and contacts guanosine residues distinct from those contacted by the BPcs, demonstrating that these two classes of proteins contain functionally distinct DNA binding domains. Assays of APRE-luciferase reporter plasmids transfected into HepG2 cells show that a mutated APRE that binds only BPi functions as an IL-1 alpha inducible enhancer, whereas a mutated APRE that binds only BPc does not. The APRE mutant that binds the C/EBP-like BPcs to the exclusion of BPi functions as an uninducible basal enhancer both in the native context of the angiotensinogen gene and when multimerized and placed upstream of a minimal angiotensinogen promoter. The wild-type APRE that binds both BPi and BPc is less inducible by IL-1 alpha than the mutated APRE that binds only BPi. Gel shift competition assays demonstrate in vitro that the mechanism of transcriptional regulation by the APRE involves a competition between BPc and the inducible BPi for binding to the APRE. IL-1 alpha stimulation of hepatocytes leads to nuclear translocation of the NF kappa B-like BPi which competes with the constitutive C/EBP-like BPcs for overlapping binding sites on the APRE and thereby replaces weak transcriptional activators with a stronger one.
血管紧张素原是强效血管加压肽血管紧张素II的糖蛋白前体,编码该蛋白的基因在急性期反应过程中,通过糖皮质激素受体与结合于急性期反应元件(APRE,5'-AGTTGGGATTTCCCAACC-3')的蛋白之间的协同相互作用,在肝细胞中被转录激活。APRE结合一组组成型蛋白(BPc)和一种细胞因子诱导蛋白(BPi),后者与核因子κB(NFκB)难以区分。通过体外结合和体内转录反式激活试验研究了纯化蛋白与APRE的相互作用。BPc是一组热稳定的DNA结合蛋白,其不同大小的成员能够形成异二聚体。BPc可被抗C/EBP抗血清识别,并在APRE上产生与细菌表达的C/EBP相似的足迹。BPi对APRE的亲和力比BPc高4至5倍,且与BPc接触的鸟苷残基不同,这表明这两类蛋白含有功能不同的DNA结合结构域。对转染入HepG2细胞的APRE-荧光素酶报告质粒的检测表明,仅结合BPi的突变APRE发挥白细胞介素-1α诱导增强子的作用,而仅结合BPc的突变APRE则不然。在血管紧张素原基因的天然背景下,以及在多聚化并置于最小血管紧张素原启动子上游时,结合C/EBP样BPc而排斥BPi的APRE突变体发挥不可诱导的基础增强子的作用。结合BPi和BPc的野生型APRE受白细胞介素-1α的诱导程度低于仅结合BPi的突变APRE。凝胶迁移竞争试验在体外证明,APRE的转录调控机制涉及BPc与诱导性BPi之间对APRE结合的竞争。白细胞介素-1α刺激肝细胞导致NFκB样BPi的核转位,后者与组成型C/EBP样BPc竞争APRE上的重叠结合位点,从而用更强的转录激活因子取代较弱的转录激活因子。